Anthem (ANTX) Competitors

Anthem has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Cybin has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Anthem's return on equity of -53.52% beat Cybin's return on equity.

Anthem is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Anthem presently has a consensus price target of $9.00, indicating a potential upside of 67.91%. Cybin has a consensus price target of $48.60, indicating a potential upside of 270.43%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Anthem.

90.5% of Anthem shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 22.6% of Anthem shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cybin had 22 more articles in the media than Anthem. MarketBeat recorded 24 mentions for Cybin and 2 mentions for Anthem. Cybin's average media sentiment score of 1.51 beat Anthem's score of 0.48 indicating that Cybin is being referred to more favorably in the news media.

Anthem's return on equity of -53.52% beat Achieve Life Sciences' return on equity.

Achieve Life Sciences presently has a consensus price target of $15.00, suggesting a potential upside of 104.92%. Anthem has a consensus price target of $9.00, suggesting a potential upside of 67.91%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Achieve Life Sciences is more favorable than Anthem.

Achieve Life Sciences has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Anthem has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Achieve Life Sciences and Achieve Life Sciences both had 2 articles in the media. Achieve Life Sciences' average media sentiment score of 1.66 beat Anthem's score of 0.48 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Anthem is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Glass House Brands presently has a consensus target price of $16.00, suggesting a potential upside of 99.68%. Anthem has a consensus target price of $9.00, suggesting a potential upside of 67.91%. Given Glass House Brands' higher probable upside, equities analysts plainly believe Glass House Brands is more favorable than Anthem.

Glass House Brands' return on equity of 0.00% beat Anthem's return on equity.

90.5% of Anthem shares are held by institutional investors. 22.6% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Glass House Brands had 5 more articles in the media than Anthem. MarketBeat recorded 7 mentions for Glass House Brands and 2 mentions for Anthem. Glass House Brands' average media sentiment score of 0.90 beat Anthem's score of 0.48 indicating that Glass House Brands is being referred to more favorably in the media.

Collegium Pharmaceutical has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Anthem has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

90.5% of Anthem shares are owned by institutional investors. 22.6% of Anthem shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 5.93% compared to Anthem's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Anthem's return on equity.

In the previous week, Collegium Pharmaceutical had 12 more articles in the media than Anthem. MarketBeat recorded 14 mentions for Collegium Pharmaceutical and 2 mentions for Anthem. Anthem's average media sentiment score of 0.48 beat Collegium Pharmaceutical's score of -0.13 indicating that Anthem is being referred to more favorably in the media.

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 67.91%. Collegium Pharmaceutical has a consensus price target of $48.50, suggesting a potential upside of 122.07%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Anthem.